Entering text into the input field will update the search result below

Novo Nordisk more than doubles sales target for obesity drugs on outlook for Wegovy

Mar. 03, 2022 3:15 PM ETNovo Nordisk A/S (NVO)By: Dulan Lokuwithana, SA News Editor2 Comments

New Nordisk

hapabapa/iStock Editorial via Getty Images

  • Novo Nordisk (NVO) expects to generate over 25B Danish crowns ($3.72B) by 2025 from its obesity drug sales driven by the demand for the once-weekly GLP-1 receptor agonist Wegovy (semaglutide), Danish drugmaker said on Thursday at its capital

Recommended For You

Comments (2)

Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

Underestimates the obesity potential. 1. the new f/c is a conservative guess and 2. those who can't afford Wegovy are using Ozempic off-label which falls into the diabetes category. Bottom line is demand for this is crazy but you don't hear about it because nobody wants to admit using it. NVO below $115 is a big buy!
Originally planned for release on Fat Tuesday, the news was delayed two days out of delicacy for patients’ feelings.

About NVO

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
Novo Nordisk A/S
Eli Lilly and Company
Johnson & Johnson
Merck & Co., Inc.
Roche Holding AG
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.